AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CHIMERIC THERAPEUTICS LTD

0.002

0.000

Volume:13.89M

Turnover:27.79K

Market Cap:8.84M

PE:-0.27

High:0.002

Open:0.002

Low:0.002

Close:0.002

52wk High:0.009

52wk Low:0.001

Shares:4.42B

Float Shares:2.91B

Volume Ratio:0.63

T/O Rate:0.48%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.008

EPS(LYR):-0.008

ROE:-1290.99%

ROA:-25.89%

PB:-2.92

PE(LYR):-0.26

Loading ...

Overview Company News Filings

BRIEF-Chimeric Therapeutics Says To Return Chlorotoxin (CHM CLTX) Car T-Cell Therapy Asset

Chimeric Therapeutics - to Return to City of Hope Chlorotoxin (Chm Cltx) Car T-Cell Therapy Asset That Co Had Exclusively Licensed

THOMSON REUTERS

BRIEF-Chimeric Therapeutics Says Phillip Hains Retires As CFO

Chimeric Therapeutics Ltd - Aaron Laurita Appointed as Chief Financial Officer

THOMSON REUTERS

Chimeric Therapeutics Ltd - Phillip Hains Retires as CFO

THOMSON REUTERS

Chimeric Therapeutics Ltd - Bradley Glover Appointed Non-Executive Chair

THOMSON REUTERS

BRIEF-Chimeric Therapeutics Announces A$8.4 MLN Funding To Drive CHM CDH17

Chimeric Therapeutics Ltd - Shares to Be Issued via Two Tranches at a$0.003 per Share

THOMSON REUTERS

Chimeric Therapeutics Ltd-$8.4 M Funding to Drive Chm Cdh17 and Resignation of Cmo

THOMSON REUTERS

Chimeric Therapeutics Ltd - All Figures in AUD

THOMSON REUTERS

BRIEF-Chimeric Therapeutics Seeks Trading Halt

Chimeric Therapeutics - Seeks Trading Halt Pending Material Capital Raising Announcement

THOMSON REUTERS

BRIEF-Chimeric Therapeutics Says CDH17 Granted FDA Orphan Drug Designation For Gastric Cancer

Chimeric Therapeutics Ltd - Cdh17 Granted FDA Orphan Drug Designation for Gastric Cancer

THOMSON REUTERS

Chimeric Therapeutics Ltd-Company Update-Board Changes, Shareholder Feedback & Support

THOMSON REUTERS

BRIEF-Chimeric Therapeutics Receives A$4.5M R&D Tax Incentive

BRIEF-Chimeric Therapeutics Says Core-Nk + Vactosertib Phase 1B Trial Temporarily Suspended

Chimeric Therapeutics Ltd-Chm Core Nk Combination Phase 1B Trial Update

THOMSON REUTERS

Chimeric Therapeutics Ltd-Pause in Trading

THOMSON REUTERS

Chimeric Therapeutics Ltd-Response to ASX Query Letter

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CHM.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CHM.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CHM.AU\",,,,,undefined,":{"symbol":"CHM.AU","market":"AU","secType":"STK","nameCN":"CHIMERIC THERAPEUTICS LTD","latestPrice":0.002,"timestamp":1772601120000,"preClose":0.002,"halted":0,"volume":13893361,"delay":0,"changeRate":0,"nameEN":"CHIMERIC THERAPEUTICS LTD","floatShares":2907076656,"shares":4418703619,"eps":-0.007542,"marketStatus":"Not Yet Opened","change":0,"latestTime":"03-04 16:12:00 AEDT","open":0.002,"high":0.002,"low":0.002,"amount":27787,"amplitude":0,"askPrice":0.003,"askSize":105567530,"bidPrice":0.002,"bidSize":250000,"shortable":3,"etf":0,"ttmEps":-0.007542,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1772665200000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.002,"openAndCloseTimeList":[[1772578800000,1772600400000]],"volumeRatio":0.6297935173225238,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CHM.AU\",,,,,undefined,":{"symbol":"CHM.AU","floatShares":2907076656,"roa":"-25.89%","roe":"-1290.99%","lyrEps":-0.007715,"volumeRatio":0.6297935173225238,"shares":4418703619,"dividePrice":0,"high":0.002,"amplitude":0,"preClose":0.002,"low":0.002,"week52Low":0.001,"pbRate":"-2.92","psRate":"0.91","week52High":0.009,"institutionHeld":0,"latestPrice":0.002,"committee":-0.995275,"eps":-0.007542,"divideRate":0,"volume":13893361,"delay":0,"ttmEps":-0.007542,"open":0.002,"prevYearClose":0.002,"prevWeekClose":0.001,"prevMonthClose":0.001,"prevQuarterClose":0.002,"fiveDayClose":0.002,"twentyDayClose":0.002,"sixtyDayClose":0.003,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CHM.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CHM.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CHM.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2614013920","title":"BRIEF-Chimeric Therapeutics Says To Return Chlorotoxin (CHM CLTX) Car T-Cell Therapy Asset","url":"https://stock-news.laohu8.com/highlight/detail?id=2614013920","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614013920?lang=en_us&edition=fundamental","pubTime":"2026-02-27 10:04","pubTimestamp":1772157854,"startTime":"0","endTime":"0","summary":"BRIEF-Chimeric Therapeutics Says To Return Chlorotoxin  Car T-Cell Therapy Asset Feb 27  - Chimeric Therapeutics Ltd CHM.AX:TO RETURN TO CITY OF HOPE CHLOROTOXIN  CAR T-CELL THERAPY ASSET THAT CO HAD EXCLUSIVELY LICENSEDFurther company coverage: CHM.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nFWN3ZM298:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CHM.AU"],"gpt_icon":0},{"id":"2614074244","title":"Chimeric Therapeutics -  to Return to City of Hope Chlorotoxin (Chm Cltx) Car T-Cell Therapy Asset That Co Had Exclusively Licensed","url":"https://stock-news.laohu8.com/highlight/detail?id=2614074244","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614074244?lang=en_us&edition=fundamental","pubTime":"2026-02-27 06:10","pubTimestamp":1772143801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nFWN3ZM298:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CHM.AU","BK7067"],"gpt_icon":0},{"id":"2611172337","title":"BRIEF-Chimeric Therapeutics Says Phillip Hains Retires As CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2611172337","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611172337?lang=en_us&edition=fundamental","pubTime":"2026-02-16 09:31","pubTimestamp":1771205513,"startTime":"0","endTime":"0","summary":"BRIEF-Chimeric Therapeutics Says Phillip Hains Retires As CFOFeb 16  - Chimeric Therapeutics Ltd CHM.AX:PHILLIP HAINS RETIRES AS CFOBRADLEY GLOVER APPOINTED NON-EXECUTIVE CHAIRAARON LAURITA APPOINTED AS CHIEF FINANCIAL OFFICERFurther company coverage: CHM.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260216:nFWN3Z91SY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CHM.AU"],"gpt_icon":0},{"id":"2611468176","title":"Chimeric Therapeutics Ltd - Aaron Laurita Appointed as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2611468176","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611468176?lang=en_us&edition=fundamental","pubTime":"2026-02-16 06:06","pubTimestamp":1771193169,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260215:nFWN3Z91SY:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CHM.AU","BK7067"],"gpt_icon":0},{"id":"2611317646","title":"Chimeric Therapeutics Ltd - Phillip Hains Retires as CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2611317646","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611317646?lang=en_us&edition=fundamental","pubTime":"2026-02-16 06:06","pubTimestamp":1771193169,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260215:nFWN3Z91SY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CHM.AU","BK7067"],"gpt_icon":0},{"id":"2611176465","title":"Chimeric Therapeutics Ltd - Bradley Glover Appointed Non-Executive Chair","url":"https://stock-news.laohu8.com/highlight/detail?id=2611176465","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611176465?lang=en_us&edition=fundamental","pubTime":"2026-02-16 06:06","pubTimestamp":1771193169,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260215:nFWN3Z91SY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CHM.AU","BK7067"],"gpt_icon":0},{"id":"2593452594","title":"BRIEF-Chimeric Therapeutics Announces A$8.4 MLN Funding To Drive CHM CDH17","url":"https://stock-news.laohu8.com/highlight/detail?id=2593452594","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593452594?lang=en_us&edition=fundamental","pubTime":"2025-12-23 09:21","pubTimestamp":1766452861,"startTime":"0","endTime":"0","summary":"BRIEF-Chimeric Therapeutics Announces A$8.4 MLN Funding To Drive CHM CDH17Dec 23  - Chimeric Therapeutics Ltd CHM.AX:$8.4 M FUNDING TO DRIVE CHM CDH17 AND RESIGNATION OF CMOSHARES TO BE ISSUED VIA TWO TRANCHES AT A$0.003 PER SHAREALL FIGURES IN AUDFurther company coverage: CHM.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nTUE5ZHSK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CHM.AU"],"gpt_icon":0},{"id":"2593455772","title":"Chimeric Therapeutics Ltd - Shares to Be Issued via Two Tranches at a$0.003 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2593455772","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593455772?lang=en_us&edition=fundamental","pubTime":"2025-12-23 06:53","pubTimestamp":1766444027,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nTUE5ZHSK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CHM.AU","BK7067"],"gpt_icon":0},{"id":"2593455721","title":"Chimeric Therapeutics Ltd-$8.4 M Funding to Drive Chm Cdh17 and Resignation of Cmo","url":"https://stock-news.laohu8.com/highlight/detail?id=2593455721","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593455721?lang=en_us&edition=fundamental","pubTime":"2025-12-23 06:53","pubTimestamp":1766444027,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nTUE5ZHSK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CHM.AU","BK7067"],"gpt_icon":0},{"id":"2593455706","title":"Chimeric Therapeutics Ltd - All Figures in AUD","url":"https://stock-news.laohu8.com/highlight/detail?id=2593455706","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593455706?lang=en_us&edition=fundamental","pubTime":"2025-12-23 06:53","pubTimestamp":1766444027,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nTUE5ZHSK:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CHM.AU","BK7067"],"gpt_icon":0},{"id":"2592187590","title":"BRIEF-Chimeric Therapeutics Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2592187590","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592187590?lang=en_us&edition=fundamental","pubTime":"2025-12-19 06:41","pubTimestamp":1766097692,"startTime":"0","endTime":"0","summary":"BRIEF-Chimeric Therapeutics Seeks Trading Halt Dec 19 (Reuters) - Chimeric Therapeutics Ltd CHM.AX:SEEKS TRADING HALT PENDING MATERIAL CAPITAL RAISING ANNOUNCEMENTFurther company coverage: CHM.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nFWN3XO160:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHM.AU","BK7067"],"gpt_icon":0},{"id":"2592182095","title":"Chimeric Therapeutics - Seeks Trading Halt Pending Material Capital Raising Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=2592182095","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592182095?lang=en_us&edition=fundamental","pubTime":"2025-12-19 06:30","pubTimestamp":1766097050,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nFWN3XO160:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CHM.AU"],"gpt_icon":0},{"id":"2589802839","title":"BRIEF-Chimeric Therapeutics Says CDH17 Granted FDA Orphan Drug Designation For Gastric Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2589802839","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589802839?lang=en_us&edition=fundamental","pubTime":"2025-12-08 08:55","pubTimestamp":1765155319,"startTime":"0","endTime":"0","summary":"BRIEF-Chimeric Therapeutics Says CDH17 Granted FDA Orphan Drug Designation For Gastric CancerDec 8 (Reuters) - Chimeric Therapeutics Ltd CHM.AX:CDH17 GRANTED FDA ORPHAN DRUG DESIGNATION FOR GASTRIC CANCERFurther company coverage: CHM.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nFWN3XC0BJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHM.AU","BK7067"],"gpt_icon":0},{"id":"2589806954","title":"Chimeric Therapeutics Ltd - Cdh17 Granted FDA Orphan Drug Designation for Gastric Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2589806954","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589806954?lang=en_us&edition=fundamental","pubTime":"2025-12-08 05:33","pubTimestamp":1765143209,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251207:nFWN3XC0BJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CHM.AU"],"gpt_icon":0},{"id":"2586278668","title":"Chimeric Therapeutics Ltd-Company Update-Board Changes, Shareholder Feedback & Support","url":"https://stock-news.laohu8.com/highlight/detail?id=2586278668","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586278668?lang=en_us&edition=fundamental","pubTime":"2025-11-28 06:27","pubTimestamp":1764282444,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251127:nTUE9CKSNP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CHM.AU"],"gpt_icon":0},{"id":"2585431981","title":"BRIEF-Chimeric Therapeutics Receives A$4.5M R&D Tax Incentive","url":"https://stock-news.laohu8.com/highlight/detail?id=2585431981","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585431981?lang=en_us&edition=fundamental","pubTime":"2025-11-24 09:45","pubTimestamp":1763948734,"startTime":"0","endTime":"0","summary":"BRIEF-Chimeric Therapeutics Receives A$4.5M R&D Tax IncentiveNov 24 (Reuters) - Chimeric Therapeutics Ltd CHM.AX:CHIMERIC RECEIVES $4.5M RESEARCH AND DEVELOPMENT TAX INCENTIVEALL FIGURES IN AUDFurther company coverage: CHM.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nTUE9RRQCD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CHM.AU"],"gpt_icon":0},{"id":"2583584428","title":"BRIEF-Chimeric Therapeutics Says Core-Nk + Vactosertib Phase 1B Trial Temporarily Suspended","url":"https://stock-news.laohu8.com/highlight/detail?id=2583584428","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583584428?lang=en_us&edition=fundamental","pubTime":"2025-11-13 07:45","pubTimestamp":1762991119,"startTime":"0","endTime":"0","summary":"BRIEF-Chimeric Therapeutics Says Core-Nk + Vactosertib Phase 1B Trial Temporarily SuspendedNov 13  - Chimeric Therapeutics Ltd CHM.AX:CHM CORE NK COMBINATION PHASE 1B TRIAL UPDATECORE-NK + VACTOSERTIB PHASE 1B TRIAL TEMPORARILY SUSPENDEDFurther company coverage: CHM.AX ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nTUE7ZJZHY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHM.AU","BK7067"],"gpt_icon":0},{"id":"2583584342","title":"Chimeric Therapeutics Ltd-Chm Core Nk Combination Phase 1B Trial Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2583584342","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583584342?lang=en_us&edition=fundamental","pubTime":"2025-11-13 07:21","pubTimestamp":1762989713,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nTUE7ZJZHY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CHM.AU","BK7067"],"gpt_icon":0},{"id":"2583581245","title":"Chimeric Therapeutics Ltd-Pause in Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2583581245","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583581245?lang=en_us&edition=fundamental","pubTime":"2025-11-13 07:09","pubTimestamp":1762988989,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nTUE8YPYFN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CHM.AU","BK7067"],"gpt_icon":0},{"id":"2581089614","title":"Chimeric Therapeutics Ltd-Response to ASX Query Letter","url":"https://stock-news.laohu8.com/highlight/detail?id=2581089614","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581089614?lang=en_us&edition=fundamental","pubTime":"2025-11-06 07:47","pubTimestamp":1762386469,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nTUE7Z40VP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CHM.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":20,"code":"91000000","status":"200"}]}}